New funding strengthens hope for life-changing therapies
It’s been a great start to the New Year for our client, Alfacyte, who has received a £250,000 investment from EOS Technology Investment Syndicate and the Scottish Investment Bank, to develop its topical treatment for the skin condition, psoriasis.
The pharma business specialises in the development of interferon therapy including applications for cancer treatments, auto-immune diseases and allergies.
This is the second round of equity funding the company has received reaffirming investors’ faith in the business.
Andy Sloane, Business Team Partner said, “Alfacyte is an exciting business making substantial progress in the field of immunology and initial findings are extremely promising. This significant investment will take the company a step closer to developing life-changing science”.
Based in BioCity Scotland, Alfacyte was founded by Bill Stimson, a former professor of immunology at the University of Strathclyde.< Back